Adaptive Biotechnologies Corp Forecast, price target & analysts
Adaptive Biotechnologies Corp Target price 2026 - Analyst rating & recommendation
Adaptive Biotechnologies Corp Classifications & Recommendation
Adaptive Biotechnologies Corp Price Target
| Target Price | $25.50 |
| Price | $28.77 |
| Deviation |
11.37%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Adaptive Biotechnologies Corp 2027 .
The average Adaptive Biotechnologies Corp target price is $25.50.
This is
11.37%
register free of charge
$29.40
2.19%
register free of charge
$21.21
26.28%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend Adaptive Biotechnologies Corp to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adaptive Biotechnologies Corp stock has an average upside potential 2027 of
11.37%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 276.98 | 299.10 |
| 54.77% | 7.99% | |
| EBITDA Margin | -16.42% | -2.38% |
| 79.74% | 85.50% | |
| Net Margin | -21.48% | -29.56% |
| 75.90% | 37.61% |
10 Analysts have issued a sales forecast Adaptive Biotechnologies Corp 2026 . The average Adaptive Biotechnologies Corp sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Adaptive Biotechnologies Corp EBITDA forecast 2026. The average Adaptive Biotechnologies Corp EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Adaptive Biotechnologies Corp Analysts have issued a net profit forecast 2026. The average Adaptive Biotechnologies Corp net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.39 | -0.56 |
| 63.89% | 43.59% | |
| P/E | negative | |
| EV/Sales | 15.32 |
10 Analysts have issued a Adaptive Biotechnologies Corp forecast for earnings per share. The average Adaptive Biotechnologies Corp EPS is
This results in the following potential growth metrics and future valuations:
Adaptive Biotechnologies Corp...
Current Adaptive Biotechnologies Corp Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 09 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 09 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
